Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Transgenics

This article was originally published in The Gray Sheet

Executive Summary

Increase in credit facility by $15 mil. to a total of $24.6 mil. is arranged through a commitment from Fleet Bank. The Framingham, Massachusetts transgenic technology spin-off of Genzyme General also has received a commitment for a $5 mil. lease line of credit with Transamerica Technology Finance. The new capital strengthens the firm's financial position and will be used in part to refinance existing debt and for expansion of production facilities. The company is developing transgenic technology to enable development and production of recombinant proteins and monoclonal antibodies for medical uses

You may also be interested in...



US Payers Rate ICER Assessment Updates Using Real World Data As Potentially ‘High Impact’

ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.

Most Pharmacies Ready For COVID-19 Vaccines; Ultra-Cold Storage Still A Limitation

Results of a forthcoming APhA survey showed about one-third cannot store Pfizer/BioNTech's BNT162b2, but can handle Moderna's mRNA-1273.

Battery Failures From Improper Cleaning Lead To Class I Recall For Baxter Infusion Pumps

Baxter has recalled more than half a million infusion pumps due to concerns improper cleaning could cause their batteries to malfunction. The recall was designated as high-risk class I by the US FDA.

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel